STOCK TITAN
  1. Home
  2. Sec-filings
  3. LTGO
  4. [Form 3] Latigo Biotherapeutics, Inc. Initial Statement of Beneficial Ownership

Latigo Biotherapeutics (LTGO) CMO lists four large option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Latigo Biotherapeutics, Inc. (LTGO) reported initial insider holdings for Chief Medical Officer Neil Singla. He holds four employee stock options for common stock: one covering 613,468 shares at an exercise price of $2.19 expiring in 2034, and three covering 293,517, 49,480, and 98,960 shares at $5.53 expiring in 2035. Footnotes describe time-based vesting, with one-fourth vesting after one year and the remainder vesting monthly over four years.

Positive

  • None.

Negative

  • None.
Insider Singla Neil
Role Chief Medical Officer
Type Security Shares Price Value
holding Employee Stock Option (right to buy) F1 -- -- --
holding Employee Stock Option (right to buy) F2 -- -- --
holding Employee Stock Option (right to buy) F2 -- -- --
holding Employee Stock Option (right to buy) F2 -- -- --
Holdings After Transaction: Employee Stock Option (right to buy) — 1,055,425 shares (Direct)
Footnotes (2)
  1. F1. One-fourth of the total shares subject to this option shall vest one year after April 1, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof.
  2. F2. One-fourth of the total shares subject to this option shall vest one year after January 28, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof.
Option exercise price $2.19 per share Employee stock option expiring July 30, 2034
Underlying shares (largest grant) 613,468 shares Common stock underlying option at $2.19 exercise price
Option exercise price (other grants) $5.53 per share Three employee stock options expiring in 2035
Underlying shares (293,517 grant) 293,517 shares Common stock underlying option at $5.53 expiring February 4, 2035
Underlying shares (49,480 grant) 49,480 shares Common stock underlying option at $5.53 expiring April 7, 2035
Underlying shares (98,960 grant) 98,960 shares Common stock underlying option at $5.53 expiring April 7, 2035
Employee Stock Option (right to buy) financial
"security_title: Employee Stock Option (right to buy)"
underlying security financial
"underlying_security_title: Common Stock"
vesting financial
"shares subject to this option shall vest one year after"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What insider holdings did LTGO’s Chief Medical Officer Neil Singla report on this Form 3?
Neil Singla reported four employee stock options for Latigo Biotherapeutics (LTGO) common stock. These options cover an aggregate of several hundred thousand shares, with exercise prices of $2.19 and $5.53, and expirations in 2034 and 2035, subject to time-based vesting.

What are the exercise prices of Neil Singla’s LTGO stock options?
Neil Singla’s LTGO options have exercise prices of $2.19 and $5.53 per share. The largest grant is at $2.19 for 613,468 underlying shares, while three additional grants at $5.53 cover 293,517, 49,480, and 98,960 underlying shares, respectively.

How many LTGO shares underlie Neil Singla’s largest reported stock option grant?
The largest reported option held by Neil Singla covers 613,468 shares of LTGO common stock. This option has a $2.19 exercise price and expires on July 30, 2034, with vesting over four years starting one year after April 1, 2024.

When do Neil Singla’s LTGO stock options expire?
Neil Singla’s LTGO options expire between 2034 and 2035. One grant at $2.19 expires on July 30, 2034, while three grants at $5.53 expire on February 4, 2035 and April 7, 2035, assuming they are not exercised earlier.

What is the vesting schedule for Neil Singla’s LTGO stock options?
Neil Singla’s LTGO options use a time-based vesting schedule. For each noted grant, one-fourth of the total shares vest one year after the grant reference date, and the remaining three-fourths vest in equal monthly installments over the next three years.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Singla Neil
(Last)(First)(Middle)
C/O LATIGO BIOTHERAPEUTICS, INC.
1300 RANCHO CONEJO BLVD., SUITE 305
(Street)
THOUSAND OAKS CALIFORNIA 91320
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
08/06/2026		3. Issuer Name and Ticker or Trading Symbol
Latigo Biotherapeutics, Inc. [ LTGO ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy) (1)07/30/2034Common Stock613,468$2.19D
Employee Stock Option (right to buy) (2)02/04/2035Common Stock293,517$5.53D
Employee Stock Option (right to buy) (2)04/07/2035Common Stock49,480$5.53D
Employee Stock Option (right to buy) (2)04/07/2035Common Stock98,960$5.53D
Explanation of Responses:
1. One-fourth of the total shares subject to this option shall vest one year after April 1, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof.
2. One-fourth of the total shares subject to this option shall vest one year after January 28, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof.
/s/ Sabrina Nieder, Attorney-in-Fact08/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR